Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05579899 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
A Phase 2 study, sponsored by Evommune.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT05579899: Completed Phase 2 study, sponsored by Evommune.
NCT05579899 is a Phase 2 study that has completed, run by Evommune. The registered enrollment target is 119 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05579899, a Phase 2 study, has completed, sponsored by Evommune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis
Primary Outcome
EASI assesses the extent and severity of atopic dermatitis. EASI is a composite index with scores ranging from 0 to 72. Higher values indicate more severe or extensive disease.
Interventions
- DRUG EVO101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2022-09-27 |
| Est. Completion | 2023-07-27 |
| Phase | Phase 2 |
What the finished NCT05579899 record still lists
NCT05579899 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower).
The record links to 0 conditions, and to 1 intervention - of which EVO101 is the first listed.
NCT05579899 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05579899 about?
NCT05579899 is a clinical study titled "Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis". This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis
What is the current status of trial NCT05579899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2022-09-27. Estimated completion is 2023-07-27.
What interventions are being tested in trial NCT05579899?
The interventions under investigation include: EVO101 (DRUG).
Who is sponsoring clinical trial NCT05579899?
This trial is sponsored by Evommune, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05579899's enrollment target sits among peer trials
119 618th of 2000 higher than 1,383 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI